Patents by Inventor Michael Paul Jennings
Michael Paul Jennings has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220372459Abstract: A mutant subtilase cytotoxin B subunit protein is provided which can bind glycans having ?2-3-linked N-glycolylneuraminic acid and glycans having ?2-6-linked N-glycolylneuraminic acid. The mutant SubB protein has deletions of one or more of the amino acid sequence TTSTE and has a previously undescribed ability to bind glycans having ?2-6-linked N-glycolylneuraminic acid, while not losing the ability to bind glycans having ?2-3-linked N-glycolylneuraminic acid.Type: ApplicationFiled: May 27, 2022Publication date: November 24, 2022Inventors: Michael Paul Jennings, Christopher Day, Adrienne Webster Paton, James Cleland Paton
-
Patent number: 11371033Abstract: A mutant subtilase cytotoxin B subunit protein is provided which can bind glycans having ?2-3-linked N-glycolylneuraminic acid and glycans having ?2-6-linked N-glycolylneuraminic acid. The mutant SubB protein has deletions of one or more of the amino acid sequence TTSTE and has a previously undescribed ability to bind glycans having ?2-6-linked N-glycolylneuraminic acid, while not losing the ability to bind glycans having ?2-3-linked N-glycolylneuraminic acid.Type: GrantFiled: November 9, 2017Date of Patent: June 28, 2022Assignees: Griffith University, The University of AdelaideInventors: Michael Paul Jennings, Christopher Day, Adrienne Webster Paton, James Cleland Paton
-
Publication number: 20190367895Abstract: A mutant subtilase cytotoxin B subunit protein is provided which can bind glycans having ?2-3-linked N-glycolylneuraminic acid and glycans having ?2-6-linked N-glycolylneuraminic acid. The mutant SubB protein has deletions of one or more of the amino acid sequence TTSTE and has a previously undescribed ability to bind glycans having ?2-6-linked N-glycolylneuraminic acid, while not losing the ability to bind glycans having ?2-3-linked N-glycolylneuraminic acid.Type: ApplicationFiled: November 9, 2017Publication date: December 5, 2019Inventors: Michael Paul Jennings, Christopher Day, Adrienne Webster Paton, James Cleland Paton
-
Patent number: 9150621Abstract: The present invention relates to the use of mutant glycoproteins from pathogenic bacteria lacking one or more phosphorylcholine and/or glycosylation post-translational modifications as immunogens. These post-translational modifications act as masking structures that elicit an immune response which does not confer protection on an infected individual. The removal or modification of these masking structures alters the protein such that it elicits a stronger immune response to the protein and/or the bacterial pathogen. Particular examples are pilin proteins and nitrite reductase glycoproteins of Neisseria bacteria.Type: GrantFiled: August 28, 2009Date of Patent: October 6, 2015Assignee: The University of QueenslandInventor: Michael Paul Jennings
-
Patent number: 8962801Abstract: Neisseria meningitidis PorA constructs are provided which have one or more disrupted variable regions created by insertion of entire conserved regions or conserved region amino acids. The highly immunogenic variable regions of PorA are responsible for eliciting strain-specific immune responses that are not broadly protective, so disruption of the variable regions directs the immune response against conserved region epitopes to effectively immunize against a broader spectrum of N. meningitidis strains. Also provided are encoding nucleic acids, genetic constructs, host cells expressing the PorA constructs and compositions, kits and methods for detection and treatment of Neisseria meningitidis infections.Type: GrantFiled: August 1, 2011Date of Patent: February 24, 2015Assignee: Griffith UniversityInventors: Michael Paul Jennings, Ian Richard Anselm Peak
-
Publication number: 20140050731Abstract: The invention relates to a vaccine for the treatment of disease caused by Neisseria, the vaccine including one or more immunogenic components for Neisseria serogroups, as well as antibodies to the immunogenic components and methods of preventing and treating Neisseria infections. The immunogens are based on elements of the inner core lipopolysaccharide.Type: ApplicationFiled: August 13, 2013Publication date: February 20, 2014Applicant: Isis Innovation Ltd.Inventors: Joyce Susan Plested, Michael Paul Jennings, Margaret Ann Jaqueline Gidney, Andrew David Cox, James Clare Richards, Edward Richard Moxon
-
Patent number: 8535688Abstract: The invention relates to a vaccine for the treatment of disease caused by Neisseria, the vaccine including one or more immunogenic components for Neisseria serogroups, as well as antibodies to the immunogenic components and methods of preventing and treating Neisseria infections. The immunogens are based on elements of the inner core lipopolysaccharide.Type: GrantFiled: December 7, 2011Date of Patent: September 17, 2013Assignee: Isis Innovation LimitedInventors: Joyce Susan Plested, Michael Paul Jennings, Margaret Ann Jaqueline Gidney, Andrew David Cox, James Clare Richards, Richard Edward Moxon
-
Publication number: 20130196901Abstract: Neisseria meningitidis PorA constructs are provided which have one or more disrupted variable regions created by insertion of entire conserved regions or conserved region amino acids. The highly immunogenic variable regions of PorA are responsible for eliciting strain-specific immune responses that are not broadly protective, so disruption of the variable regions directs the immune response against conserved region epitopes to effectively immunize against a broader spectrum of N. meningitidis strains. Also provided are encoding nucleic acids, genetic constructs, host cells expressing the PorA constructs and compositions, kits and methods for detection and treatment of Neisseria meningitidis infections.Type: ApplicationFiled: August 1, 2011Publication date: August 1, 2013Applicant: GRIFFITH UNIVERISTYInventors: Michael Paul Jennings, Ian Richard Anselm Peak
-
Publication number: 20130085262Abstract: The invention provides a novel surface polypeptide from Neisseria meningitidis as well as nucleic acid and nucleic acid sequence homologues encoding this protein. Pharmaceutical compositions containing the polypeptide and nucleic acids of the invention are also disclosed as well as methods useful in the treatment, prevention and diagnosis of N. meningitidis infection.Type: ApplicationFiled: September 14, 2011Publication date: April 4, 2013Applicant: The University of QueenslandInventors: Ian Richard Anselm PEAK, Michael Paul Jennings, E. Richard Moxon
-
Patent number: 8383790Abstract: Novel proteins that constitute modified forms of a Neisseria meningitidis surface antigen and encoding nucleic acids are provided. The modified surface proteins are characterized by having deletions of non-conserved amino acids, and thereby being capable of eliciting cross-protective immune responses against Neisseria meningitidis. The invention extends to the use of the modified surface antigens in diagnostics, in therapeutic and prophylactic vaccines and in the design and/or screening of medicaments. The modified surface antigens are particularly useful in vaccines which effectively immunize against a broader spectrum of N. meningitidis strains than would be expected from a corresponding wild-type surface antigen.Type: GrantFiled: October 31, 2007Date of Patent: February 26, 2013Assignee: The University of QueenslandInventors: Ian Richard Anselm Peak, Michael Paul Jennings
-
Patent number: 8367070Abstract: Novel proteins that constitute modified forms of a Neisseria meningitidis surface antigen and encoding nucleic acids are provided. The modified surface proteins are characterized by having deletions of non-conserved amino acids, and thereby being capable of eliciting cross-protective immune responses against Neisseria meningitidis. The invention extends to the use of the modified surface antigens in diagnostics, in therapeutic and prophylactic vaccines and in the design and/or screening of medicaments. The modified surface antigens are particularly useful in vaccines which effectively immunize against a broader spectrum of N. meningitidis strains than would be expected from a corresponding wild-type surface antigen.Type: GrantFiled: October 31, 2007Date of Patent: February 5, 2013Assignee: The University of QueenslandInventors: Ian Richard Anselm Peak, Michael Paul Jennings
-
Publication number: 20120121646Abstract: The invention relates to a vaccine for the treatment of disease caused by Neisseria, the vaccine including one or more immunogenic components for Neisseria serogroups, as well as antibodies to the immunogenic components and methods of preventing and treating Neisseria infections. The immunogens are based on elements of the inner core lipopolysaccharide.Type: ApplicationFiled: December 7, 2011Publication date: May 17, 2012Applicant: Isis Innovation LimitedInventors: Joyce Susan Plested, Michael Paul Jennings, Margaret Ann Jaqueline Gidney, Andrew David Cox, James Clare Richards, Richard Edward Moxon
-
Publication number: 20120123093Abstract: The invention provides a novel surface polypeptide from Neisseria meningitidis as well as nucleic acid and nucleic acid sequence homologues encoding this protein. Pharmaceutical compositions containing the polypeptide and nucleic acids of the invention are also disclosed as well as methods useful in the treatment, prevention and diagnosis of N. meningitidis infection.Type: ApplicationFiled: September 14, 2011Publication date: May 17, 2012Applicant: The University of QueenslandInventors: Ian Richard Anselm PEAK, Michael Paul Jennings, E. Richard Moxon
-
Patent number: 8173798Abstract: The invention relates to a vaccine for the treatment of disease caused by Neisseria, the vaccine including one or more immunogenic components for Neisseria serogroups, as well as antibodies to the immunogenic components and methods of preventing and treating Neisseria infections. The immunogens are based on elements of the inner core lipopolysaccharide.Type: GrantFiled: July 24, 2009Date of Patent: May 8, 2012Assignee: Isis Innovation LimitedInventors: Joyce Susan Plested, Michael Paul Jennings, Margaret Anne Jaqueline Gidney, Andrew David Cox, James Clare Richards, Richard Edward Moxon
-
Patent number: 8148499Abstract: The invention relates to a vaccine for the treatment of disease caused by Neisseria, the vaccine comprising one or more immunogenic components for Neisseria serogroups, as well as antibodies to the immunogenic components and methods of preventing and treating Neisseria infections. The immunogens are based on elements of the inner core lipopolysaccharide.Type: GrantFiled: February 14, 2011Date of Patent: April 3, 2012Assignee: Isis Innovation Ltd.Inventors: Joyce Susan Plested, Michael Paul Jennings, Margaret Ann Jaqueline Gidney, Andrew David Cox, James Clare Richards, Edward Richard Moxon
-
Patent number: 8067004Abstract: The invention provides a novel surface polypeptide from Neisseria meningitidis as well as nucleic acid and nucleic acid sequence homologues encoding this protein. Pharmaceutical compositions containing the polypeptide and nucleic acids of the invention are also disclosed as well as methods useful in the treatment, prevention and diagnosis of N. meningitidis infection.Type: GrantFiled: August 11, 2003Date of Patent: November 29, 2011Assignee: The University of QueenslandInventors: Ian Richard Anseim Peak, Michael Paul Jennings, E. Richard Moxon
-
Publication number: 20110262476Abstract: The present invention relates to the use of mutant glycoproteins from pathogenic bacteria lacking one or more phosphorylcholine and/or glycosylation post-translational modifications as immunogens. These post-translational modifications act as masking structures that elicit an immune response which does not confer protection on an infected individual. The removal or modification of these masking structures alters the protein such that it elicits a stronger immune response to the protein and/or the bacterial pathogen. Particular examples are pilin proteins and nitrite reductase glycoproteins of Neisseria bacteria.Type: ApplicationFiled: August 28, 2009Publication date: October 27, 2011Inventor: Michael Paul Jennings
-
Patent number: 8034358Abstract: The invention provides a novel surface polypeptide from Neisseria meningitidis as well as nucleic acid and nucleic acid sequence homologues encoding this protein. Pharmaceutical compositions containing the polypeptide and nucleic acids of the invention are also disclosed as well as methods useful in the treatment, prevention and diagnosis of N. meningitidis infection.Type: GrantFiled: July 12, 2007Date of Patent: October 11, 2011Assignee: The University of QueeslandInventors: Ian Richard Anselm Peak, Michael Paul Jennings, E. Richard Moxon
-
Publication number: 20110171234Abstract: The invention relates to a vaccine for the treatment of disease caused by Neisseria, the vaccine comprising o more immunogenic components for Neisseria serogroups, as well as antibodies to the immunogenic components and m preventing and treating Neisseria infections.Type: ApplicationFiled: February 14, 2011Publication date: July 14, 2011Applicant: Isis Innovation LimitedInventors: Joyce Susan Plested, Michael Paul Jennings, Margaret Ann Jaqueline Gidney, Andrew David Cox, James Clare Richards, Edward Richard Moxon
-
Patent number: 7947291Abstract: Novel proteins that constitute modified forms of a Neisseria meningitidis surface antigen and encoding nucleic acids are provided. The modified surface proteins are characterized by having deletions of non-conserved amino acids, and thereby being capable of eliciting cross-protective immune responses against Neisseria meningitidis. The invention extends to the use of the modified surface antigens in diagnostics, in therapeutic and prophylactic vaccines and in the design and/or screening of medicaments. The modified surface antigens are particularly useful in vaccines which effectively immunize against a broader spectrum of N. meningitidis strains than would be expected from a corresponding wild-type surface antigen.Type: GrantFiled: January 25, 2001Date of Patent: May 24, 2011Assignee: The University of QueenslandInventors: Ian Richard Anselm Peak, Michael Paul Jennings